The role of glucagon-like peptide-1 receptor agonists for the treatment of adolescent obesity

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)315-317
Number of pages3
JournalExpert Review of Endocrinology and Metabolism
Issue number4
StatePublished - Jul 2013

Bibliographical note

Funding Information:
AS Kelly has received research funding from Amylin/Eli Lilly and served on a pediatric obesity advisory board (clinical trial design) for Novo Nordisk. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.


  • glucagon-like peptide-1 receptor agonists
  • pediatric obesity
  • pharmacotherapy

Cite this